Large Inflow of Money Witnessed in Rosetta Genomics Ltd.

Rosetta Genomics Ltd. (NASDAQ:ROSG): $0.02 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 40.65. The value of trades done on upticks was $0.02 million, whereas, trades done on downticks were valued at $0 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.02 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.02 million. Rosetta Genomics Ltd. (NASDAQ:ROSG) fell $0.03 traded at $1.08, a change of -2.7% over the previous day. The stock is -5.26% for the week.


Institutional Investors own 4.47% of Rosetta Genomics Ltd. shares.

The company shares have dropped -67.06% from its 1 Year high price. On Jul 6, 2015, the shares registered one year high at $3.44 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $1.14 and the 200 Day Moving Average price is recorded at $1.14. Rosetta Genomics Ltd. (NASDAQ:ROSG): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.14 and $1.08 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.12, notching a gain of 0.90% for the day. The total traded volume was 329,193 . The stock had closed at $1.11 on the previous day.

Rosetta Genomics Ltd. is a molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has developed platform technologies for the identification, extraction, quantification and analysis of microRNAs from a range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects in cancer, cardiovascular diseases and other indications. The Companys four commercial oncology tests have been launched in multiple countries across the world. The Company is working to develop additional tests in the cancer realm and in other fields. It is marketing and selling the four diagnostic tests based on its microRNA technologies, which include Rosetta Cancer Origin Test, Rosetta Lung Cancer Test, Rosetta Kidney Cancer Test and Rosetta Mesothelioma Test. The Companys therapeutic pipeline consists of the projects, such as CMV Therapeutic and Rimonim Consortium.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.